Clinical Trial Detail

NCT ID NCT02829723
Title Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

glioblastoma multiforme

pancreatic cancer

triple-receptor negative breast cancer

Therapies

BLZ945

BLZ945 + Spartalizumab

Age Groups: adult senior

No variant requirements are available.